Taisho Pharmaceutical Co., Ltd.
https://www.taisho.co.jp/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Taisho Pharmaceutical Co., Ltd.
Cipla's Advair Generic Debut In Sight, More Platform Deals On Radar Post Ethris
Cipla believes it is “pretty close” to approval for its Advair generic in the US, while another product, generic Abraxane, stands delayed currently. Following the deal with Ethris, which is progressing inhaled mRNA-based therapies, the company signals interest in platforms such as CAR-T as well.
Hikma Could Consider Exit Strategy For Generics Business
Hikma says all options are on the table for its beleaguered generics business, with an immediate sale unlikely but the door open for a longer-term exit strategy. Meanwhile, the firm has also offered an update on recruitment for a new CEO.
Hikma Adds Another Celltrion Biosimilar To MENA Collaboration
Hikma has further expanded its portfolio of biosimilars in the MENA region with the addition of Celltrion’s Vegzelma bevacizumab rival to Avastin. Meanwhile, Hikma has also just launched a new pre-filled syringe version of naloxone in the US.
Hikma Delivers On Authorized Xyrem In US
Hikma has begun 2023 with the long-awaited launch of a US authorized generic version of Xyrem (sodium oxybate). Meanwhile, the company has also struck a deal with Junshi Biosciences for toripalimab in the MENA region.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
- Transdermal
-
Drug Delivery
- Other Names / Subsidiaries
-
- Hoepharma Holdings Sdn. Bhd.
- Taisho Toyama Pharmaceutical Co., Ltd.
- TOKUHON Corporation
- UPSA SAS
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice